{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:16:37Z","timestamp":1794244597252,"version":"4.9.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.esmoop.2025.104513","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T03:14:02Z","timestamp":1742958842000},"page":"104513","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Advances in individualization of systemic treatment for locoregionally advanced nasopharyngeal carcinoma: a systematic review"],"prefix":"10.1016","volume":"10","author":[{"given":"P.","family":"Blanchard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"De Felice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.L.K.","family":"Chua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmoop.2025.104513_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.esmoop.2025.104513_bib2","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2020.12.007","article-title":"Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Bossi","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2025.104513_bib3","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.esmoop.2025.104513_bib7","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","article-title":"Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma","volume":"381","author":"Zhang","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.esmoop.2025.104513_bib8","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1200\/JCO.22.00327","article-title":"Final overall survival analysis of gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma: a multicenter, randomized phase III trial","volume":"40","author":"Zhang","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.104513_bib9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.radonc.2021.12.029","article-title":"Identifying optimal clinical trial candidates for locoregionally advanced nasopharyngeal carcinoma: analysis of 9468 real-world cases and validation by two phase 3 multicentre, randomised controlled trial","volume":"167","author":"Tang","year":"2022","journal-title":"Radiother Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.104513_bib10","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","article-title":"Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial","volume":"17","author":"Sun","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2025.104513_bib11","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211052417","article-title":"Development of a risk classification system combining TN-categories and circulating EBV DNA for non-metastatic NPC in 10,149 endemic cases","volume":"13","author":"Chen","year":"2021","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.104513_bib12","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1038\/s41467-019-11853-y","article-title":"Liquid biopsy tracking during sequential chemo-radiotherapy identifies distinct prognostic phenotypes in nasopharyngeal carcinoma","volume":"10","author":"Lv","year":"2019","journal-title":"Nat Commun"},{"issue":"10445","key":"10.1016\/j.esmoop.2025.104513_bib13","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1016\/S0140-6736(24)00594-4","article-title":"Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial","volume":"403","author":"Liu","year":"2024","journal-title":"Lancet"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2025.104513_bib15","volume":"42","author":"Mai","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2025.104513_bib17","article-title":"NEOSPACE trial: neoadjuvant pembrolizumab-gemcitabine-cisplatin followed by concurrent pembrolizumab-chemoradiation and maintenance pembrolizumab for stage IVA nasopharyngeal cancer (NPC)","volume":"41","author":"Hui","year":"2023","journal-title":"J\u00a0Clinic Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.104513_bib18","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/s41467-024-45126-0","article-title":"Camrelizumab and apatinib plus induction chemotherapy and concurrent chemoradiotherapy in stage N3 nasopharyngeal carcinoma: a phase 2 clinical trial","volume":"15","author":"Liang","year":"2024","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.esmoop.2025.104513_bib19","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1200\/JCO.21.01467","article-title":"Deintensified chemoradiotherapy for pretreatment Epstein-Barr virus DNA-selected low-risk locoregionally advanced nasopharyngeal carcinoma: a phase II randomized noninferiority trial","volume":"40","author":"Li","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.104513_bib21","author":"gov"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2025.104513_bib22","doi-asserted-by":"crossref","first-page":"6001","DOI":"10.1200\/JCO.2023.41.16_suppl.6001","article-title":"Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: an open-label, non-inferiority, randomized phase 3 trial","volume":"41","author":"Chen","year":"2023","journal-title":"J\u00a0Clinic Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2025.104513_bib23","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/S1470-2045(23)00232-2","article-title":"Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"24","author":"Liu","year":"2023","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.104513_bib24","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1001\/jamaoncol.2022.4656","article-title":"Adjuvant capecitabine following concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a randomized clinical trial","volume":"8","author":"Miao","year":"2022","journal-title":"JAMA Oncol"},{"issue":"10297","key":"10.1016\/j.esmoop.2025.104513_bib25","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(21)01123-5","article-title":"Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial","volume":"398","author":"Chen","year":"2021","journal-title":"Lancet"},{"issue":"suppl 17","key":"10.1016\/j.esmoop.2025.104513_bib27","article-title":"Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): a multicenter, open-label, phase 3, randomized controlled trial","volume":"42","author":"Ma","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.104513_bib29","article-title":"Analysis of plasma Epstein-Barr virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: a randomized controlled trial","author":"Chan","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.104513_bib30","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.annonc.2020.03.289","article-title":"Integrating postradiotherapy plasma Epstein-Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy","volume":"31","author":"Hui","year":"2020","journal-title":"Ann Oncol"},{"issue":"24","key":"10.1016\/j.esmoop.2025.104513_bib33","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1056\/NEJMoa032260","article-title":"Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma","volume":"350","author":"Lin","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2025.104513_bib34","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijrobp.2014.01.052","article-title":"Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid","volume":"89","author":"Twu","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.esmoop.2025.104513_bib35","volume":"7","author":"Yang","year":"2022","journal-title":"Adv Radiat Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.104513_bib36","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/annonc\/mdu117","article-title":"Plasma Epstein-Barr viral DNA load\u00a0at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma","volume":"25","author":"Leung","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2025.104513_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2024.106938","article-title":"The efficacy of adjuvant chemotherapy in patients with different midpoint-radiotherapy Epstein-Barr virus DNA plasma loads","volume":"156","author":"Chen","year":"2024","journal-title":"Oral Oncol"},{"issue":"10192","key":"10.1016\/j.esmoop.2025.104513_bib4","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.esmoop.2025.104513_bib5","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1470-2045(23)00163-8","article-title":"Role of chemotherapy in patients with nasopharynx carcinoma treated with radiotherapy (MAC-NPC): an updated individual patient data network meta-analysis","volume":"24","author":"Petit","year":"2023","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2025.104513_bib6","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/cac2.12218","article-title":"The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma","volume":"41","author":"Tang","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.esmoop.2025.104513_bib48","series-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017"},{"issue":"11","key":"10.1016\/j.esmoop.2025.104513_bib20","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1200\/JCO.22.00099","article-title":"Identifying patients with low-risk locoregionally advanced nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA for chemotherapy deintensification: Quo Vadis?","volume":"40","author":"Ng","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.104513_bib26","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1470-2045(11)70320-5","article-title":"Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial","volume":"13","author":"Chen","year":"2012","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.104513_bib28","doi-asserted-by":"crossref","first-page":"772","DOI":"10.2174\/156652412800792589","article-title":"Tissue biomarkers for prostate cancer radiation therapy","volume":"12","author":"Tran","year":"2012","journal-title":"Curr Mol Med"},{"issue":"10","key":"10.1016\/j.esmoop.2025.104513_bib31","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1158\/1078-0432.CCR-20-3519","article-title":"Dynamic changes of post-radiotherapy plasma Epstein-Barr virus DNA in a randomized trial of adjuvant chemotherapy versus observation in nasopharyngeal cancer","volume":"27","author":"Hui","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2025.104513_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2023.106655","article-title":"Longitudinal post-radiotherapy plasma Epstein-Barr virus DNA trends inform on optimal risk stratification in endemic nasopharyngeal carcinoma","volume":"148","author":"Neo","year":"2024","journal-title":"Oral Oncol"},{"key":"10.1016\/j.esmoop.2025.104513_bib38","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ejca.2021.09.005","article-title":"Nasopharyngeal cancer in non-endemic areas: impact of treatment intensity within a large retrospective multicentre cohort","volume":"159","author":"Bossi","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2025.104513_bib40","author":"gov"},{"key":"10.1016\/j.esmoop.2025.104513_bib43","article-title":"Impact of plasma Epstein-Barr virus-DNA and tumor volume on prognosis of locally advanced nasopharyngeal carcinoma","volume":"2015","author":"Chen","year":"2015","journal-title":"Biomed Res Int"},{"issue":"3","key":"10.1016\/j.esmoop.2025.104513_bib44","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.ijrobp.2006.05.064","article-title":"Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma","volume":"66","author":"Ma","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"10.1016\/j.esmoop.2025.104513_bib45","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1158\/1078-0432.CCR-12-3702","article-title":"An international collaboration to harmonize the quantitative plasma Epstein-Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma","volume":"19","author":"Le","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"29","key":"10.1016\/j.esmoop.2025.104513_bib46","doi-asserted-by":"crossref","first-page":"47780","DOI":"10.18632\/oncotarget.17822","article-title":"Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area","volume":"8","author":"Alfieri","year":"2017","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.esmoop.2025.104513_bib47","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/jamaoncol.2024.4354","article-title":"Ninth version of the AJCC and UICC nasopharyngeal cancer TNM staging classification","volume":"10","author":"Pan","year":"2024","journal-title":"JAMA Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925003825?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925003825?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T10:44:02Z","timestamp":1762598642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925003825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2059702925003825"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.104513","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in individualization of systemic treatment for locoregionally advanced nasopharyngeal carcinoma: a systematic review","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.104513","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"104513"}}